Mr. Blom joined Modus in 2019 from dual-listed Zealand Pharma, where he was CFO from 2010. During his tenure, he oversaw the Company’s 2010 IPO on Nasdaq OMX Copenhagen, raising USD 50 million, a 2016 USD 22 million Directed issue and a 2017 listing on Nasdaq Global Markets in New York raising USD 90 million. Prior to that Mr Blom was CFO at Swedish Orphan International.
Dr. Öhd joined Modus as Chief Medical Officer in March 2018 from Medivir AB, where he was CMO and a member of the company’s Executive Management team. Before taking up his current position, John was Medivir’s Director of Clinical R&D. Prior to joining Medivir, John was Senior Director of Experimental Medicine at Shire based in Nyon, Switzerland. Between 2007 and 2012, Dr. Öhd held several positions of increasing responsibility at AstraZeneca in Södertalje, Sweden.
Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF). He has been trustee/committee member of the HIV Research Trust, the Wellcome Trust and World Health Organisation. Professor Wahlgren has received a Fogarty Award, the Harford Visiting Professorship at Washington University, the Söderberg professorship of the Royal Swedish Academy of Sciences and a ‘Distinguished Professor Award‘ from Karolinska Institutet. He is a member of the Nobel assembly. Professor Wahlgren is co-founder of Modus Therapeutics and several other biotech companies.
Ellen K. Donnelly, Ph.D., joined Modus Therapeutics in 2017 from Pfizer, where she held various leadership positions in Clinical Operations, Project and Portfolio Management and Research. Most recently Dr. Donnelly was responsible for Clinical Operations for Pfizer’s Neuroscience and Pain therapeutic area. Dr. Donnelly also brings biotech and management consulting experience to the CEO role. Dr. Donnelly received her Ph.D. from Yale University.